Akebia Therapeutics (NASDAQ:AKBA) & Lucid Diagnostics (NASDAQ:LUCD) Head to Head Survey

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Earnings and Valuation

This table compares Akebia Therapeutics and Lucid Diagnostics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akebia Therapeutics $236.20 million 0.53 -$5.34 million ($0.16) -2.83
Lucid Diagnostics $5.44 million 15.29 -$58.01 million ($0.40) -1.02

Akebia Therapeutics has higher revenue and earnings than Lucid Diagnostics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Akebia Therapeutics and Lucid Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akebia Therapeutics -22.60% -156.59% -11.53%
Lucid Diagnostics -892.75% N/A -142.71%

Insider & Institutional Ownership

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Akebia Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Akebia Therapeutics and Lucid Diagnostics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akebia Therapeutics 1 2 4 0 2.43
Lucid Diagnostics 1 0 4 0 2.60

Akebia Therapeutics presently has a consensus target price of $3.50, indicating a potential upside of 674.34%. Lucid Diagnostics has a consensus target price of $4.19, indicating a potential upside of 923.84%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Akebia Therapeutics.

Summary

Lucid Diagnostics beats Akebia Therapeutics on 8 of the 13 factors compared between the two stocks.

About Akebia Therapeutics

(Get Free Report)

Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for people affected by kidney disease. Founded in 2007 and based in Cambridge, Massachusetts, the company’s work has centered on anemia and other complications associated with chronic kidney disease. Its products include Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and Auryxia (ferric citrate).

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics is a U.S.-based medical diagnostics company focused on identifying esophageal precancer and cancer. Its primary offering is EsoGuard, a DNA-based test designed to detect cellular changes associated with Barrett’s esophagus, a condition that can increase the risk of esophageal cancer. The test is designed to work with EsoCheck, a swallowable balloon device that collects cells from the esophagus for analysis. Together, the products are intended to provide a less invasive approach to evaluating patients for esophageal disease than traditional endoscopic procedures.

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.